• ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • LEGAL & INVESTMENT TEAM
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • FINANCIAL CALENDAR
    • ANALYST COVERAGE
    • AIM RULE 26
    • FUNDRAISING
  • NEWS
  • CONTACT US
Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"
NCSI (LON) 48.50 GBX
  • ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • LEGAL & INVESTMENT TEAM
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • FINANCIAL CALENDAR
    • ANALYST COVERAGE
    • AIM RULE 26
    • FUNDRAISING
  • NEWS
  • CONTACT US

Netscientific Appoints Ian Postlethwaite as CFO

Apr 5, 2016
-
News, RNS Announcements
RNS Number : 1367U
NetScientific PLC
05 April 2016

(“NetScientific” or the “Company” or the “Group”)

 

Netscientific Appoints Ian Postlethwaite as Chief Financial Officer

London, UK – 5th April 2016 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic biomedical and healthcare technology  group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer.  Ian will join the Company and the Board as soon as his current employer has appointed a suitable successor and allowed time for an orderly handover. A subsequent announcement detailing Ian’s start date will be made in due course.

Ian Postlethwaite is currently the Finance Director and Company Secretary of Allergy Therapeutics plc, where he has held the roles since May 2002. Ian previously held senior finance and executive management positions with AFS (1997-2002), Ericsson (1994-1997) and Phillips Electronics (1989-1994). Ian is a Fellow of the Chartered Association of Certified Accountants. He graduated from Aston University in 1985 with a BSc (Hons) in Geological Sciences.

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific, said: “I am delighted to welcome Ian to NetScientific as our new Chief Financial Officer. His wealth of experience at Board level in raising capital for listed growth companies with international operations in the healthcare sector will be a huge asset to the Company as we move forward with our new focus on digital health, diagnostics and therapeutics.

“We very much look forward to working with Ian as he becomes a pivotal member of our team. Until he commences Mark Nanovich will continue in his role as Interim CFO, and we would like to thank Mark for his continued contribution in helping to support the business during our recent period of transition.”

Ian Postlethwaite commented: “I am excited to be joining NetScientific – this is a rapidly progressing group with an exciting portfolio of high-quality assets focused on dynamic new areas in healthcare. I look forward to working with the team to build value.”

Ian David Postlethwaite, aged 53 years, has been a director of the following companies during the five years preceding the date of this announcement:

 Current directorships

Past Directorships

Allergy Therapeutics plc

Allergy Therapeutics Developments

Allergy Therapeutics (Holdings) Limited

Limited

Bencard Allergie GmbH

Allergy Therapeutics Italia s.r.l.

Allergy Therapeutics Iberia S.L.

Sussex Port Forwarding Limited

Shoreham Port Developments And Investments Limited

Teomed AG

 

There is no further information to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies.

– Ends –

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

Tel: +44 (0)20 3514 1800

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment.  For more information, please visit the website at www.netscientific.net.

This information is provided by RNS
The company news service from the London Stock Exchange

END

BOALFFEISRISIIR

FacebookTweetGoogle+Linkedin
← PREVIOUS POST
Annual Financial Report
NEXT POST →
ProAxsis Forms Scientific Advisory Board
News
  • Directors Dealing
  • Results of General Meeting
  • Vortex Biosciences to Present Compelling Liquid Biopsy Data in Collaboration with Stanford University School of Medicine and UCLA at AACR 2018
  • Upcoming Investor Conferences
  • Results of Placing, Subscription and Additional Fundraising
INVESTORS
  • Investors
  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • AIM Rule 26
  • News
Categories
  • Glycotest
  • Media
  • News
  • PDS Biotechnology
  • ProAxsis
  • RNS Announcements
  • Vortex BioSciences
  • Wanda Health
Archives
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • March 2014
  • February 2014
  • September 2013

NetScientific plc

6 Bevis Marks
1st floor, Bury Court
London
EC3A 7BA

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • Investors
  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • AIM Rule 26
  • News
copyright
Terms of Use
Netscientific Appoints Ian Postlethwaite as CFO - NetScientific